USE OF AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENT TO AMELIORATE INFLAMMATION

摘要

Use of an anti-vascular endothelial growth factor (VEGF) agent for the manufacture of a medicament to ameliorate inflammation at a site in the body that may be the eye, a joint, the brain, etc. or to reduce corneal neovascularization. In one embodiment, one or more other agents, such as non-steroidal anti-inflammatory agents, steroids, etc., may be included with the anti-VEGF agent. The anti-VEGF agent may be bevacizumab, ranibizumab, sunitinib maleate, pegaptanib, etc.